Sarepta Therapeutics, Inc.: Form 10-Q for the period ended Mar 31, 2023
Filed with the SEC on May 2, 2023 and accepted by EDGAR at May 2, 2023, 16:02 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-01-01 to 2023-03-31 | $231.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Selling, general and administrative | 3 months2023-01-01 to 2023-03-31 | $110.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-01-01 to 2023-03-31 | −$138.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-01-01 to 2023-03-31 | $6.3m | us-gaap:InterestExpense |
| Income tax | 3 months2023-01-01 to 2023-03-31 | $4.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-01-01 to 2023-03-31 | −$516.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-01-01 to 2023-03-31 | −$5.86 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-01-01 to 2023-03-31 | −$5.86 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-01-01 to 2023-03-31 | 88,186,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2023-01-01 to 2023-03-31 | −$209.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2023-01-01 to 2023-03-31 | $9.5m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-03-31 | $871.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-03-31 | $2.49bn | us-gaap:AssetsCurrent |
| Total assets | At period end2023-03-31 | $3.06bn | us-gaap:Assets |
| Current liabilities | At period end2023-03-31 | $536.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-03-31 | $2.35bn | us-gaap:Liabilities |
| Long-term debt | At period end2023-03-31 | $1.23bn | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2023-03-31 | $712.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-23-016654. Last ingested by Listed: Oct 24, 2026, 14:58 ET. Listed shows no prices and gives no investment advice.